Ergotamine Gangrene in Various Inflammatory Conditions

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Given in subtoxic doses to the rat, ergotamine produced tail gangrene in not more than 20% of animals. The incidence rate of ergotamine gangrene was not influenced by acute Mammation (carrageenin, dextran oedema). However, when inflammation was produced by immersing the tail of the rat in dimethyl sulfoxide, the incidence rate of ergotamine gangrene was greatly increased. The gangrene-inducing effect of ergotamine was significantly increased in rats with adjuvant arthritis or 6-sulphanylamido-indazole arthritis. Like arthritic rats, rats with lathyrism due to chronic treatment with aminoacetonitrile were also more sensitive to the gangrene-inducing effect of ergotamine. Ergotamine-induced tail gangrene in adjuvant arthritic rats is a good model for use in research for drugs which are effective against the vascular complications of ‘collagen’ diseases.

Related collections

Author and article information

Journal

Journal ID (publisher-id): JVR

Journal ID (nlm-ta): J Vasc Res

Journal ID (doi): 10.1159/issn.1018-1172

Title: Journal of Vascular Research

Publisher: S. Karger AG

ISSN (Print): 1018-1172

ISSN (Electronic): 1423-0135

Publication date Subscription-year: 1971

Publication date (Print): 1971

Publication date (Electronic): 18 September 2008

Volume: 8

Issue: 1

Pages: 57-64

Affiliations

EGYT Pharmacochemical Works and Otto Korvin Hospital, Budapest

Article

Publisher ID: 157860 Other ID: Angiologica 1971;8:57–64

DOI: 10.1159/000157860

SO-VID: e69d4e1f-10a5-4707-b5dc-f3a1898761de

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Ergotamine Gangrene in Various Inflammatory Conditions

Read this article at

Abstract

Related collections

Karger: Cardiovascular System

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 317